TNI’s novel softFlow technology is designed to provide high flow, warmed and humidified respiratory gases to spontaneously breathing patients suffering from pulmonary disease

masi

Image: Masimo has announced investment in pulmonary care company TNI medical. Photo: courtesy of Robert-Owen-Wahl from Pixabay.

Masimo, a global leader in innovative noninvasive monitoring technologies, today announced it has closed on a strategic investment with TNI medical AG (“TNI”), a privately held, commercial-stage medical device company headquartered in Würzburg, Germany.

TNI’s novel softFlow technology is designed to provide high flow, warmed and humidified respiratory gases to spontaneously breathing patients suffering from pulmonary disease. The softFlow technology provides efficient and comfortable respiratory support by generating a precisely regulated, stable high flow of room air or a mix of room air and oxygen.

The system, comprised of an integrated flow generator, respiratory circuit, and patient interface, operates without the need of pneumatic systems (i.e. compressed air supplied from the hospital wall) and can be used both in the hospital and at home.

“The innovative products TNI has developed provide clinicians with important additional tools to address the growing number of people affected by pulmonary diseases,” said Joe Kiani, Founder, Chairman, and CEO of Masimo. “We are happy to provide TNI with an investment that will allow the company to continue to commercialize its products in the large and fast growing High Flow Nasal Therapy market.”

Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions.

Source: Company Press Release